What insurance does a cell and gene therapy company need?

A cell and gene therapy (CGT) company is a clinical-stage biotech with the volume turned up. It needs the same core lines - clinical trial liability for subject injury, directors and officers once outside capital arrives, general liability and property, workers compensation, and cyber for research and patient data - but the limits are higher and two exposures are unusually demanding: the length of the claims tail, and the manufacturing.

The tail is the defining feature. FDA expects long-term follow-up of up to 15 years for gene therapies that integrate into the genome or persist, so an adverse event can be attributed to the product more than a decade after a subject was dosed. That reshapes how the whole program has to be maintained.

CGT trials, especially first-in-human gene therapy, carry the highest per-subject uncertainty in clinical research: the intervention is often irreversible, the mechanism is novel, and the populations are frequently rare-disease or pediatric. Clinical trial liability for these studies commonly runs $10M-$25M and can go higher for pivotal or multi-country programs, with per-subject sub-limits scrutinized closely by ethics committees.

The coverage form matters as much as the limit. Because injuries can surface years later, the trial-liability program has to be maintained continuously and backed with tail coverage at close-out (see below).

FDA guidance calls for long-term follow-up of gene-therapy subjects for as long as 15 years to monitor delayed adverse events such as insertional oncogenesis. Most clinical trial liability and products coverage is claims-made, which only responds to claims reported while coverage (or a tail) is in force. A CGT company that lets a claims-made policy lapse at trial close-out without an extended reporting period leaves a decade-plus window of delayed-injury exposure uninsured.

The practical structure is continuous claims-made coverage with retroactive dates preserved across renewals and carriers, plus a long extended reporting period (tail) purchased at any close-out or carrier change. Gene-therapy tail is materially more expensive than ordinary biotech tail, and it should be budgeted from the start rather than discovered at wind-down.

CGT manufacturing carries exposures a small-molecule or standard biologic does not. Viral-vector production and cell processing are contamination-sensitive and hard to re-validate after a loss. Autologous therapies are patient-specific: a batch made from a single patient's cells cannot simply be remade, so a manufacturing loss or a chain-of-identity error can mean a patient goes untreated, which is both a clinical and a liability event. Cryogenic storage and cold-chain transport add property and cargo exposures, and chain-of-identity and chain-of-custody requirements create process-failure risk.

These translate into needs for property with validation and reprocessing coverage, cargo and cold-chain coverage, and products/completed operations and professional coverage tuned to the CGT process rather than a generic manufacturer form.

CGT companies tend to carry high valuations and intense scrutiny, so a single safety event can move the stock and draw securities litigation - D&O is sized to the valuation and the clinical calendar, with public-company language added ahead of an IPO. The CGT field is also IP-litigation-heavy (platform and vector patent disputes), so intellectual-property and technology exposure is worth addressing. General liability, workers compensation (lab and manufacturing class codes), and cyber round out the program.